Scilex announces issuance of new patent in U.S. for ZTlido

Scilex Holding announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,793,766, further strengthening the Company’s intellectual property position and coverage for its lead commercial product, ZTlido 1.8%. The Patent, titled “Non-aqueous Patch for the Relief of Pain,” covers a method of relieving pain through the application of a lidocaine-containing patch. “The newly issued Patent demonstrates our commitment to offer innovative, non-opioid pain management products and to develop meaningfully differentiated programs that address significant unmet needs leading to improved health outcomes for the millions of acute and chronic pain patients. Our growing intellectual property portfolio provides significant barriers of entry, protects us from would be competitors, and gives us confidence in long-term growth opportunity for ZTlido(R),” said Jaisim Shah, Chief Executive Officer and President of Scilex.